These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17014899)

  • 21. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
    Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
    Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
    Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
    Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
    Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
    Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of recurrent ovarian cancer--a retrospective study].
    Tkácová M; Belohorská B; Sevcíková K; Hel'pianska L; Ondrus D; Ondrusová M; Spánik S
    Klin Onkol; 2010; 23(2):115-23. PubMed ID: 20465091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent micropapillary serous ovarian carcinoma.
    Bristow RE; Gossett DR; Shook DR; Zahurak ML; Tomacruz RS; Armstrong DK; Montz FJ
    Cancer; 2002 Aug; 95(4):791-800. PubMed ID: 12209723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Value of tumor-reductive secondary operation (interventional laparotomy) in ovarian cancer].
    Meier W; Römisch M; Hepp H
    Geburtshilfe Frauenheilkd; 1993 Dec; 53(12):860-5. PubMed ID: 8119569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum.
    Gronlund B; Lundvall L; Christensen IJ; Knudsen JB; Høgdall C
    Eur J Surg Oncol; 2005 Feb; 31(1):67-73. PubMed ID: 15642428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
    Obermair A; Sevelda P
    Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.
    Bristow RE; Lagasse LD; Karlan BY
    Cancer; 1996 Nov; 78(10):2049-62. PubMed ID: 8918397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
    Zang R; Zhang Z; Cai S
    Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of obesity on survival in patients with ovarian cancer.
    Matthews KS; Straughn JM; Kemper MK; Hoskins KE; Wang W; Rocconi RP
    Gynecol Oncol; 2009 Feb; 112(2):389-93. PubMed ID: 19062080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Scarabelli C; Gallo A; Carbone A
    Gynecol Oncol; 2001 Dec; 83(3):504-12. PubMed ID: 11733963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tertiary cytoreduction in patients with recurrent ovarian carcinoma.
    Leitao MM; Kardos S; Barakat RR; Chi DS
    Gynecol Oncol; 2004 Oct; 95(1):181-8. PubMed ID: 15385129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
    Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
    Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.